Part 4/7:
Despite the revenue slump, Gilead maintained around a 90% market share in most regions. The company has also seen positive developments in its government contracts, particularly with the Veterans Affairs Department, which has begun treating more veterans with Gilead's hepatitis C medications. This have collectively resulted in approximately 700,000 Americans being cured from hepatitis C, marking a significant public health achievement.
Nonetheless, the strategy of maintaining market dominance has come with costs. To keep its share, Gilead has been forced to cut prices, which has negatively affected its bottom line. This price competition underscores the challenges the company faces in sustaining growth solely from its existing product line.